綠葉製藥(02186.HK)與阿斯利康就心血管及腫瘤領域深度合作
綠葉製藥(02186.HK)與阿斯利康共同簽署戰略合作備忘錄,雙方將積極探索在心血管及腫瘤領域的深度合作,圍繞綠葉製藥在心血管領域的天然藥物血脂康膠囊、腫瘤領域的創新制劑力撲素以及綠葉製藥旗下山東博安生物技術有限公司開發的抗腫瘤生物藥貝伐珠單抗注射液(LY01008),希望在市場覆蓋、渠道拓展、醫學研究、國際合作等方面能整合雙方優勢資源,助推優質創新藥品惠及更多中國乃至全球患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.